Post Conference Survey: CASL Single Topic Conference on Steatotic Liver Disease

We would appreciate your feedback on this conference. Your opinions are important and will assist us in planning future events. Please note, your survey responses are anonymous.

Please select your professional role

Please specify your professional role

Please indicate your current area of focus

Please specify your current area of focus

Country of residence

Scientific Program Evaluation: Availability of Conference Information

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Scientific Program Evaluation: Relevance of Conference Content

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Scientific Program Evaluation: Relevance of Conference Speakers

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Scientific Program Evaluation: Program Layout

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Scientific Program Evaluation: Length of Overall Meeting

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Scientific Program Evaluation: Time Allotment per Day

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

The meeting met the stated objectives: Through expert‑led sessions and interactive discussions, the meeting aimed to: 1) Advance understanding of disease mechanisms and progression; 2) Showcase innovations in diagnosis and patient stratification; 3) Review emerging pharmacological and non‑pharmacological therapies; 4) Highlight current and future directions in patient management

Yes

Other (please specify)

Please specify: The meeting met the stated objectives

Overall, the meeting was free of commercial bias

Yes

Other (please specify)

Please specify: Overall, the meeting was free of commercial bias

Overall, the meeting was evidence based

Yes

Other (please specify)

Please specify: Overall, the meeting was evidence based

Attending this meeting will increase, improve, or positively impact my (check all that apply)

Knowledge

Competence

Delivery of Care

Patient Outcomes

No Change

Other (please specify)

Please specify: this meeting will increase, improve, or positively impact my...

Please indicate any changes that you plan to make in your practice as a result of the information you received at this meeting?

What barriers might stop you from making the above changes to your practice?

Do you think these changes will affect patient outcomes?

Yes (please specify in what way)

No (please specify why not)

Please specify: in what way(s) these changes will affect patient outcomes

Please specify: why these changes will not affect patient outcomes

Please provide ideas for future topics or meetings

Any other general comments?

SURVEY PART 2 - Session-Specific Evaluation

In this part of the post-conference survey, you will be asked to provide your feedback on the session attended and whether the session-specific learning objectives are met. Please complete the survey fully in order for your responses to be accounted for.

FRIDAY, SEPTEMBER 18 PROGRAM

Did you attend Opening Keynote Lecture on Friday, September 18?

Yes

Keynote Presentation on From ‘Best Buys’ to ‘Right Now’: Global Policy Levers for Liver Health with Jeffrey Lazarus

Opening Keynote Lecture: Met session objectives

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Opening Keynote Lecture: Scientifically sound

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Opening Keynote Lecture: Free of commercial bias

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Opening Keynote Lecture: Enough time for discussion

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Opening Keynote Lecture: Will influence my practice

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

Opening Keynote Lecture Feedback: Other (please specify)

SATURDAY, SEPTEMBER 19 PROGRAM

Did you attend any of the Saturday, September 19 programming?

Yes

STC Session I - Epidemiology (Causes) & Prevention

From NAFLD to SLD: Precision, Stigma, and Clinical Consequences (Tie to Diabetes/CASL guidelines) with Giada Sebastiani
Alcohol and SLD: Beyond Consumption to Risk Context with Jennifer Flemming
Obesity, Metabolism, and the SLD Continuum with Michael Tsoukas
Food and physical activity and Liver Health: The Hidden Drivers with Chantal Bemeur
Q&A /Panel: Prevention at Scale: What Actually Works? with all speakers

Did you attend the STC Session I - Epidemiology (Causes) & Prevention?

Yes

STC Session I - Epidemiology (Causes) & Prevention: Met session objectives

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session I - Epidemiology (Causes) & Prevention: Scientifically sound

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session I - Epidemiology (Causes) & Prevention: Free of commercial bias

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session I - Epidemiology (Causes) & Prevention: Enough time for discussion

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session I - Epidemiology (Causes) & Prevention: Will influence my practice

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session I - Feedback: Other (please specify)

STC Session II - Early Detection/Pathways

Finding SLD Earlier: From Tools to Real-World Pathways with Nicola Pugliese
Why Screening Fails: Implementation barriers in Canadian Care Pathways with Sahar Saeed
Task-Shifting in Action: Nurse-Led Models for SLD Care with Magdalena Kuczynski
Q&A /Panel: Scaling Detection: What Will It Take? with all speakers

Did you attend the STC Session II - Early Detection/Pathways?

Yes

STC Session II - Early Detection/Pathways: Met session objectives

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session II - Early Detection/Pathways: Scientifically sound

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session II - Early Detection/Pathways: Free of commercial bias

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session II - Early Detection/Pathways: Enough time for discussion

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session II - Early Detection/Pathways: Will influence my practice

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session II - Feedback: Other (please specify)

STC Session III - Panel Discussion: Taking Care of People, Not Organs: Advancing Equitable and Person-Centered Care in the SLD Era

Perspectives from the Fatty Liver Alliance (FLA) with Michael Betel
Perspectives from Le Réseau de recherche sur la santé cardiométabolique, le diabète et l’obésité (CMDO) with Fannie Lajeunesse-Trempe

Did you attend STC Session III - Panel Discussion: Taking Care of People, Not Organs: Advancing Equitable and Person-Centered Care in the SLD Era?

Yes

STC Session III - Panel Discussion: Taking Care of People, Not Organs: Advancing Equitable and Person-Centered Care in the SLD Era

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session III - Panel Discussion: Taking Care of People, Not Organs: Advancing Equitable and Person-Centered Care in the SLD Era

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session III - Panel Discussion: Taking Care of People, Not Organs: Advancing Equitable and Person-Centered Care in the SLD Era

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session III - Panel Discussion: Taking Care of People, Not Organs: Advancing Equitable and Person-Centered Care in the SLD Era

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session III - Panel Discussion: Taking Care of People, Not Organs: Advancing Equitable and Person-Centered Care in the SLD Era

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session III - Feedback: Other (please specify)

STC Session IV – Therapeutic Innovation

Metabolic Management: The Endocrinology Perspective on SLD with Vanessa Tardio
Pathways for management Hepatology with Alnoor Ramji
Frontline SLD Care: The Role of Primary Care with James Kim
Cardiovascular risk assessment in patients with MASLD with George Thanassoulis
What’s Coming Next? Inside the MASH Pipeline with Mark Swain
Q&A /Panel: Who Should Be Treated—and by Who? with all speakers

Did you attend the STC Session IV – Therapeutic Innovation?

Yes

STC Session IV - Therapeutic Innovation: Met session objectives

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session IV - Therapeutic Innovation: Scientifically sound

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session IV - Therapeutic Innovation: Free of commercial bias

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session IV - Therapeutic Innovation: Enough time for discussion

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session IV - Therapeutic Innovation: Will influence my practice

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session IV - Feedback: Other (please specify)

STC Session V - No One-Size-Fits-All

Women and SLD: Hormones, Risk, and Missed Opportunities with Monika Sarkar
Early Life, Lifelong Risk: Pediatric SLD with Mohit Kehar
Gender-Diverse Health and SLD: Gaps and Opportunities with Tzu-Hao (Howard) Lee
Q&A /Panel: Who are we missing? with all speakers

Did you attend the STC Session V - No One-Size-Fits-All?

Yes

STC Session V - No One-Size-Fits-All: Met session objectives

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session V - No One-Size-Fits-All: Scientifically sound

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session V - No One-Size-Fits-All: Free of commercial bias

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session V - No One-Size-Fits-All: Enough time for discussion

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session V - No One-Size-Fits-All: Will influence my practice

1. Poor | 2. Fair | 3. Good | 4. Very Good | 5. Excellent

STC Session V - Feedback: Other (please specify)

I confirm I have attended the sessions rated

Opening Keynote Lecture = 1 credit

STC Session I = 1.5 credits

STC Session II = 1 credit

STC Session III = 1.5 credits

STC Session IV = 1.5 credits

STC Session V = 1 credit

SURVEY PART 1 - Overall CASL STC 2026 Evaluation

SURVEY PART 2 - Session-Specific Evaluation

FRIDAY, SEPTEMBER 18 PROGRAM

SATURDAY, SEPTEMBER 19 PROGRAM

STC Session I - Epidemiology (Causes) & Prevention

STC Session II - Early Detection/Pathways

STC Session III - Panel Discussion: Taking Care of People, Not Organs: Advancing Equitable and Person-Centered Care in the SLD Era

STC Session IV – Therapeutic Innovation

STC Session V - No One-Size-Fits-All